SCHEMBL3746094

SCHEMBL3746094

O=[N+]([O-])C1CNC1[N+](=O)[O-]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18507656 0.97
Nitric Acid SCHEMBL18507668 0.93 CA5A (0.36)
SCHEMBL9921591 0.69 CCR5 (0.32)
SCHEMBL10793901 0.65
SCHEMBL28394988 0.64 ALDH1A1 (0.35)
SCHEMBL8409243 0.64
SCHEMBL28392434 0.64 MEN1 (0.33)
SCHEMBL11804153 0.59
SCHEMBL9323765 0.59 GSR (0.36)
SCHEMBL700571 0.57 ALDH1A1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161548-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EPICENTRX, INC. (US) 2025-05-22 US claimed
US-20250099666-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EPICENTRX, INC. (US) 2025-03-27 US claimed
US-12109348-B2 Medication infusion devices, systems, and methods EPICENTRX, INC. (US) 2024-10-08 US claimed
US-12048793-B2 Medication infusion devices, systems, and methods EPICENTRX, INC. (US) 2024-07-30 US claimed
CN-111432858-B Drug infusion device, system and method 埃皮森特RX股份有限公司 2024-06-25 CN claimed
US-20230391868-A1 COMPOSITIONS FOR AND METHODS OF TREATING CANCER THE GEORGE WASHINGTON UNIVERSITY 2023-12-07 US claimed
CN-115243741-A Drug infusion device, system and method 埃皮辛特瑞柯斯公司 2022-10-25 CN claimed
EP-4072617-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EpicentRx, Inc. (US) 2022-10-19 EP claimed
WO-2022109227-A1 COMBINED CANCER THERAPY OF B7-H3 AND CD47 IMMUNE CHECKPOINT INHBITIOR AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-05-27 WO claimed
US-20210244870-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EPICENTRX, INC. 2021-08-12 US claimed
WO-2021119433-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EPICENTRX, INC. (US) 2021-06-17 WO claimed
US-20210178050-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EPICENTRX, INC. 2021-06-17 US claimed
EP-3801678-A1 MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS EpicentRx, Inc. (US) 2021-04-14 EP claimed
CN-111432858-A Drug infusion device, system and method 埃皮森特RX股份有限公司 2020-07-17 CN claimed
US-20170066716-A1 ENERGETIC N-SUBSTITUTED 3, 3-DINITROAZETIDINE PLASTICIZER AND PREPARATION METHOD THEREOF AGENCY FOR DEFENSE DEVELOPMENT (KR) 2017-03-09 US claimed
US-9573894-B1 Energetic N-substituted 3, 3-dinitroazetidine plasticizer and preparation method thereof AGENCY FOR DEFENSE DEVELOPMENT (KR) 2017-02-21 US claimed
US-20260053963-A1 RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF BREAST CANCER ACTINIUM PHARMACEUTICALS, INC. 2026-02-26 US disclosed
US-12551584-B1 Lewis Y radioimmunotherapy for the treatment of cancer ACTINIUM PHARMACEUTICALS, INC. 2026-02-17 US disclosed
US-5808099-A ADNAZ, compositions and processes THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1998-09-15 US disclosed
WO-1996036602-A1 ADNAZ, COMPOSITIONS AND PROCESSES THE UNITED STATES OF AMERICA (US) 1996-11-21 WO disclosed